Future directions for the discovery of natural product-derived immunomodulating drugs

Wainwright, C. L. et al. (2022) Future directions for the discovery of natural product-derived immunomodulating drugs. Pharmacological Research, 177, 106076. (doi: 10.1016/j.phrs.2022.106076) (PMID:35074524)

[img] Text
263735.pdf - Published Version
Available under License Creative Commons Attribution.

10MB

Abstract

Drug discovery from natural sources is going through a renaissance, having spent many decades in the shadow of synthetic molecule drug discovery, despite the fact that natural product-derived compounds occupy a much greater chemical space than those created through synthetic chemistry methods. With this new era comes new possibilities, not least the novel targets that have emerged in recent times and the development of state-of-the-art technologies that can be applied to drug discovery from natural sources. Although progress has been made with some immunomodulating drugs, there remains a pressing need for new agents that can be used to treat the wide variety of conditions that arise from disruption, or over-activation, of the immune system; natural products may therefore be key in filling this gap. Recognising that, at present, there is no authoritative article that details the current state-of-the-art of the immunomodulatory activity of natural products, this in-depth review has arisen from a joint effort between the International Union of Basic and Clinical Pharmacology (IUPHAR) Natural Products and Immunopharmacology, with contributions from a Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation number of world-leading researchers in the field of natural product drug discovery, to provide a “position statement” on what natural products has to offer in the search for new immunomodulatory argents. To this end, we provide a historical look at previous discoveries of naturally occurring immunomodulators, present a picture of the current status of the field and provide insight into the future opportunities and challenges for the discovery of new drugs to treat immune-related diseases.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Maffia, Professor Pasquale
Authors: Wainwright, C. L., Teixeira, M. M., Adelson, D. L., Buenz, E. J., David, B., Glaser, K. B., Harata-Lee, Y., Howes, M.-J. R., Izzo, A. A., Maffia, P., Mayer, A. M.S., Mazars, C., Newman, D. J., Nic Lughadha, E., Pimenta, A. M.C., Parra, J. A.A., Qu, Z., Shen, H., Spedding, M., and Wolfender, J.-L.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Research Centre:College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology
Journal Name:Pharmacological Research
Publisher:Elsevier
ISSN:1043-6618
ISSN (Online):1096-1186
Published Online:21 January 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in Pharmacological Research 177: 106076
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record